AstraZeneca Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	58,127	54,073	45,811	44,351	37,417	26,617
Revenue	58,127	54,073	45,811	44,351	37,417	26,617
Revenue Growth (YoY)	13.52%	18.04%	3.29%	18.53%	40.58%	9.16%
Cost of Revenue	9,732	9,638	8,040	8,641	12,005	5,246
Gross Profit	48,395	44,435	37,771	35,710	25,412	21,371
Selling, General & Admin	19,228	19,453	18,025	17,460	14,673	11,586
Research & Development	13,573	12,243	10,373	9,669	8,049	5,901
Other Operating Expenses	-313	-190	-275	-231	-207	-486
Operating Expenses	32,488	31,506	28,123	26,898	22,515	17,001
Operating Income	15,907	12,929	9,648	8,812	2,897	4,370
Interest Expense	-1,300	-1,403	-1,219	-917	-776	-738
Interest & Investment Income	176	345	301	81	43	77
Earnings From Equity Investments	-12	-28	-12	-5	-64	-27
Currency Exchange Gain (Loss)	-42	-42	-34	-16	-20	-34
Other Non Operating Income (Expenses)	-134	-134	-292	-370	-478	-487
EBT Excluding Unusual Items	14,595	11,667	8,392	7,585	1,602	3,161
Merger & Restructuring Charges	-1,334	-1,154	-604	-4,201	-1,283	-251
Gain (Loss) on Sale of Investments	-	-	-	-	776	-
Gain (Loss) on Sale of Assets	60	60	292	216	509	1,055
Asset Writedown	-1,574	-1,574	-434	-241	-2,069	-252
Legal Settlements	-48	-48	-1,013	-789	-48	9
Other Unusual Items	-260	-260	266	-69	248	194
Pretax Income	11,439	8,691	6,899	2,501	-265	3,916
Income Tax Expense	2,035	1,650	938	-792	-380	772
Earnings From Continuing Operations	9,404	7,041	5,961	3,293	115	3,144
Minority Interest in Earnings	-5	-6	-6	-5	-3	52
Net Income	9,399	7,035	5,955	3,288	112	3,196
Net Income to Common	9,399	7,035	5,955	3,288	112	3,196
Net Income Growth	44.71%	18.14%	81.11%	2835.71%	-96.50%	139.40%
Shares Outstanding (Basic)	1,550	1,550	1,549	1,548	1,418	1,312
Shares Outstanding (Diluted)	1,562	1,563	1,562	1,560	1,427	1,313
Shares Change (YoY)	-0.08%	0.06%	0.13%	9.32%	8.68%	0.92%
EPS (Basic)	6.06	4.54	3.84	2.12	0.08	2.44
EPS (Diluted)	6.02	4.50	3.81	2.11	0.08	2.44
EPS Growth	45.02%	18.11%	80.57%	2571.43%	-96.76%	137.39%
Free Cash Flow	12,658	9,937	8,984	8,717	4,872	3,838
Free Cash Flow Per Share	8.10	6.36	5.75	5.59	3.41	2.92
Dividend Per Share	3.130	3.100	2.900	2.900	2.870	2.800
Dividend Growth	5.39%	6.90%	-	1.04%	2.50%	-
Gross Margin	83.26%	82.18%	82.45%	80.52%	67.92%	80.29%
Operating Margin	27.37%	23.91%	21.06%	19.87%	7.74%	16.42%
Profit Margin	16.17%	13.01%	13.00%	7.41%	0.30%	12.01%
Free Cash Flow Margin	21.78%	18.38%	19.61%	19.66%	13.02%	14.42%
EBITDA	20,416	17,567	14,224	13,744	6,701	6,990
EBITDA Margin	35.12%	32.49%	31.05%	30.99%	17.91%	26.26%
D&A For EBITDA	4,509	4,638	4,576	4,932	3,804	2,620
EBIT	15,907	12,929	9,648	8,812	2,897	4,370
EBIT Margin	27.37%	23.91%	21.06%	19.87%	7.74%	16.42%
Effective Tax Rate	17.79%	18.98%	13.60%	-	-	19.71%
Revenue as Reported	58,127	54,073	45,811	44,351	37,417	26,617

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.